Xbrane Biopharma AB (XBRANE) — Working Capital to Net Assets Ratio
Xbrane Biopharma AB (XBRANE) has a Working Capital to Net Assets ratio of 44.5% as of March 2026. Working capital of Skr245.07 Million (current assets of Skr365.67 Million minus current liabilities of Skr120.60 Million) is measured against net assets of Skr550.16 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Xbrane Biopharma AB free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xbrane Biopharma AB Working Capital to Net Assets (2012–2025)
This chart shows how Xbrane Biopharma AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 44.5%, reflecting working capital of Skr245.07 Million against net assets of Skr550.16 Million SEK. See XBRANE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Xbrane Biopharma AB market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.5% | Skr322.47 Million | Skr560.65 Million | Skr375.13 Million | Skr52.66 Million | ▲ +24.9 pp |
| 2024 | 32.6% | Skr67.96 Million | Skr208.54 Million | Skr605.90 Million | Skr537.94 Million | ▼ -46.3 pp |
| 2023 | 78.9% | Skr135.14 Million | Skr171.34 Million | Skr461.69 Million | Skr326.56 Million | ▲ +13.7 pp |
| 2022 | 65.2% | Skr276.95 Million | Skr424.89 Million | Skr513.52 Million | Skr236.57 Million | ▼ -13.9 pp |
| 2021 | 79.1% | Skr341.34 Million | Skr431.74 Million | Skr561.01 Million | Skr219.67 Million | ▲ +7.1 pp |
| 2020 | 72.0% | Skr185.49 Million | Skr257.71 Million | Skr374.48 Million | Skr188.99 Million | ▲ +13.2 pp |
| 2019 | 58.8% | Skr108.32 Million | Skr184.32 Million | Skr247.94 Million | Skr139.62 Million | ▲ +58.4 pp |
| 2018 | 0.3% | Skr277.00K | Skr83.07 Million | Skr161.66 Million | Skr161.38 Million | ▼ -11.2 pp |
| 2017 | 11.5% | Skr10.21 Million | Skr88.41 Million | Skr28.10 Million | Skr17.89 Million | ▼ -23.5 pp |
| 2016 | 35.1% | Skr37.64 Million | Skr107.30 Million | Skr43.53 Million | Skr5.88 Million | ▲ +68.7 pp |
| 2015 | -33.6% | Skr-15.97 Million | Skr47.51 Million | Skr7.43 Million | Skr23.40 Million | ▼ -131.5 pp |
| 2014 | 97.9% | Skr6.17 Million | Skr6.30 Million | Skr6.56 Million | Skr390.70K | ▼ -2.1 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr88.11K | Skr657.01K | Skr568.90K | — |